FDA expands approval of nogapendekin alfa inbakicept-pmln for bladder cancer
The agency approved the drug, marketed as Anktiva, for use with BCG in adults with BCG-unresponsive non-muscle invasive bladder cancer.
The FDA approved an expanded indication for nogapendekin alfa inbakicept-pmln on October 14, 2026. The drug, marketed as Anktiva and made by Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc., is now approved for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle invasive bladder cancer.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.